Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China

Introduction: Oral semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that improves glycated hemoglobin levels and body weight in patients with type 2 diabetes (T2DM). We aim to evaluate the cost-effectiveness of once-daily oral semaglutide in comparison to placebo and injectable G...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Zhen, Tong, Wai Kei, Zhang, Xinyue, Tang, Zhijia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445164/
https://www.ncbi.nlm.nih.gov/pubmed/37621313
http://dx.doi.org/10.3389/fphar.2023.1226778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445164/
https://www.ncbi.nlm.nih.gov/pubmed/37621313
http://dx.doi.org/10.3389/fphar.2023.1226778

Ejemplares similares